SCHEMBL5506446

SCHEMBL5506446

O=S(=O)(O)CC(F)CNC1CCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
ANPEP P15144 2/20 0.41
ERAP2 Q6P179 2/20 0.41
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
SCN1A P35498 1/20 0.33
SCN2A Q99250 1/20 0.33
SCN3A Q9NY46 1/20 0.33
GRIN2B Q13224 2/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA7 P43166 1/20 0.32
CA14 Q9ULX7 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
KMT2A Q03164 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
EPHX1 P07099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5505906 0.98 KDM4E (0.48) KDM4EANPEPERAP2HTTSMN1; SMN2
SCHEMBL5506825 0.98 KDM4E (0.48) KDM4EANPEPERAP2HTTSMN1; SMN2
SCHEMBL5500654 0.93 KDM4E (0.35) KDM4EANPEPERAP2GRIN2B
SCHEMBL21518360 0.79 KDM4E (0.46) KDM4EANPEPERAP2HTTSMN1; SMN2
SCHEMBL157010 0.79 KDM4E (0.66) KDM4EANPEPERAP2HTTSMN1; SMN2
SCHEMBL5447671 0.79 KDM4E (0.66) KDM4EANPEPERAP2HTTSMN1; SMN2
SCHEMBL2142228 0.79 KDM4E (0.66) KDM4EANPEPERAP2HTTSMN1; SMN2
SCHEMBL4662686 0.77 KDM4E (0.48) KDM4EANPEPERAP2HTTSMN1; SMN2
SCHEMBL21623904 0.77 KDM4E (0.48) KDM4EANPEPERAP2HTTSMN1; SMN2
SCHEMBL1442829 0.77 KDM4E (0.63) KDM4EANPEPERAP2HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828111-A2 METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES Neurochem (International) Limited (CH) 2007-09-05 EP disclosed
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed
WO-2006059252-A2 METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR KDM4E 4725/4885ANPEP 382/4885ERAP2 994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.